The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.
 
Wataru Okamoto
Research Funding - MSD
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma
Research Funding - Ono Pharmaceutical
Other Relationship - Abbott Japan; Chugai Pharma
 
Manabu Shiozawa
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; TOWA; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Tadamichi Denda
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst)
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoshinori Kagawa
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Yukiya Narita
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Taito Esaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Izawa
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi; Taiho Pharmaceutical
 
Koji Ando
No Relationships to Disclose
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Takeshi Kato
Honoraria - Bayer; Chugai Pharma; Lilly; Sanofi; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Fumio Nagashima
Speakers' Bureau - Chugai Pharma; Janssen; Kyowa Hakko Kirin; Merck Serono; Mitsubishi Tanabe Pharma; Nestle health science; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - Taiho Pharmaceutical
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Kiwamu Akagi
Consulting or Advisory Role - Takeda
Speakers' Bureau - AstraZeneca Japan; MSD K.K; Novartis; Takeda